Unresolved issues in the prevention and treatment of venous thromboembolism

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue SUPPL. 2, 2002, Pages 33-40

  Agnelli, Giancarlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Factor Xa inhibitors; Heparin; Low molecular weight heparin; Prophylaxis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; COUMARIN DERIVATIVE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; XIMELAGATRAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; FIBRINOLYTIC AGENT; POLYSACCHARIDE; THROMBIN;

AGE; BLEEDING TENDENCY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; GENETIC PREDISPOSITION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; META ANALYSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS; ARTICLE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG ANTAGONISM; METABOLISM; RISK FACTOR; THROMBOEMBOLISM;

CLINICAL TRIALS; DALTEPARIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FACTOR VIIA; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; POLYSACCHARIDES; RISK FACTORS; THROMBIN; THROMBOEMBOLISM;

EID: 0036283397     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-32317     Document Type: Conference Paper

References (45)

1. Incidence of venous thromboembolism in hospitalized patients vs community residents
2. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis
3. Predictors of survival after deep vein thrombosis and pulmonary embolism. A population-based, cohort study
4. The clinical course of pulmonary embolism
5. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED)
6. Prevention of venous thromboembolism
7. Selective inhibition of coagulation factors: Advancing antithrombotic therapy
8. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: Meta-analysis based on original patient data
9. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis
10. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis
11. Low-molecular-weight heparins: Are they interchangeable?
12. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study
13. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective
14. New anticoagulant drugs
15. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement
16. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. A phase 2 dose-finding study
17. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I
18. The oral direct thrombin inhibitor ximelagatran (pINN, formerly H 376/95) and its subcutaneous form melagatran compared with enoxaparin as thromboprophylaxis after total hip or total knee replacement
19. Randomized, double-blind, comparative study of ximelagatran (pINN, formerly H 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty (TKA)
20. Methro II: Dose-response study of the novel oral, direct thrombin inhibitor, H 376/95 and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip or total knee replacement
21. Pharmacokinetics of Org31540/SR90107A in young and elderly healthy subjects: A highly favourable pharmacokinetic profile
22. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hipreplacement surgery: A randomised double-blind trial
23. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: A randomised double-blind comparison
24. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery
25. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
26. Overview of the clinical results of pentasaccharide in major orthopedic surgery
27. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study
28. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation
29. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement
30. The rationale for long-term prophylaxis of venous thromboembolism
31. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
32. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
33. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
34. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish Prolonged Prophylaxis (DaPP) Study
35. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients. A double-blind, randomized comparison
36. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement
37. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: A systematic review
38. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty - A meta-analysis
39. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: A randomized, double-blind, placebo-controlled trial
40. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of the randomised trials
41. Building effective prophylaxis of deep vein thrombosis in the outpatient setting
42. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis
43. Antithrombotic therapy for venous thromboembolic disease
44. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism